ArticleFrontiers in oncology2025
Intracranial neuroendocrine carcinoma with coexisting pituitary adenoma: a case report and comprehensive literature review.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroendocrine carcinomas (NECs) originating from intracranial sites are exceedingly rare. Here, we present the case of a 29-year-old female with intracranial NEC coexisting with a pituitary adenoma (PA). The patient's symptoms included intermittent headaches, visual impairment, and endocrine abnormalities. Imaging studies revealed a large lobulated mass in the left frontal lobe and a mass lesion in the sellar region. Laboratory investigations indicated elevated levels of prolactin (PRL) and growth hormone (GH). Surgical resection of the frontal lobe tumor was performed initially, followed by neuroendoscopic transsphenoidal resection of the sellar lesion. The case underscores the diagnostic complexity of intracranial NEC due to its nonspecific clinical and radiological manifestations. Surgery remains the primary treatment modality, with adjunctive radiotherapy and chemotherapy. Further research is essential to enhance diagnostic accuracy and refine treatment strategies for intracranial NEC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.